本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Cogent Biosciences, Inc.

12.07
-0.0150-0.12%
成交量:75.44万
成交额:913.30万
市值:16.85亿
市盈率:-4.79
高:12.27
开:11.95
低:11.87
收:12.08
52周最高:12.97
52周最低:3.72
股本:1.40亿
流通股本:9,913.91万
量比:0.94
换手率:0.76%
股息:- -
股息率:- -
每股收益(TTM):-2.5207
每股收益(LYR):-2.4616
净资产收益率:-107.55%
总资产收益率:-53.15%
市净率:35.77
市盈率(LYR):-4.90

数据加载中...

2024/02/14

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/02/14

重要事件披露

Form 8-K - Current report
2024/02/13

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/02/09

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/05

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2023/12/11

重要事件披露

Form 8-K - Current report
2023/11/07

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/02

重要事件披露

Form 8-K - Current report
2023/08/08

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/08/08

重要事件披露

Form 8-K - Current report
2023/08/08

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2023/06/14

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2023/06/08

重要事件披露

Form 8-K - Current report
2023/06/08

重要事件披露

Form 8-K - Current report
2023/06/06

重要事件披露

Form 8-K - Current report
2023/06/01

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2023/05/09

重要事件披露

8-K - Current report
2023/05/09

季度报告

10-Q - Quarterly report [Sections 13 or 15(d)]
2023/03/14

员工持股计划

S-8 - Securities to be offered to employees in employee benefit plans
2023/03/14

年度报告

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]